Literature DB >> 28217268

Anti-Musk Positive Myasthenia Gravis and Three Semiological Cardinal Signs.

André P C Matta1, Ana C Andorinho F Ferreira1, Arielle Kirmse1, Anna Carolina Damm1, João Gabriel D I B Farinhas1, Mariane D Barbosa1, Mayara C M Teles1, Camila Fiorelli2, Rossano Fiorelli2, Osvaldo J M Nascimento1, Marco Orsini3.   

Abstract

Myasthenia gravis (MG) is a relatively uncommon disorder with an annual incidence of approximately 7 to 9 new cases per million. The prevalence is about 70 to 165 per million. The prevalence of the disease has been increasing over the past five decades. This is thought to be due to better recognition of the condition, aging of the population, and the longer life span of affected patients. MG causes weakness, predominantly in bulbar, facial, and extra-ocular muscles, often fluctuating over minutes to weeks, in the absence of wasting, sensory loss, or reflex changes. The picture of fluctuating, asymmetric external ophthalmoplegia with ptosis and weak eye closure is virtually diagnostic of myasthenia. We report an atypical MG case with three semiological cardinal signs.

Entities:  

Keywords:  Medicine; Neurology; Neuromuscular diseases

Year:  2014        PMID: 28217268      PMCID: PMC5226044          DOI: 10.4081/ni.2016.6361

Source DB:  PubMed          Journal:  Neurol Int        ISSN: 2035-8385


  9 in total

1.  [Diagnosis, differential diagnosis and laboratory examinations in myasthenia gravis].

Authors:  Tomihiro Imai
Journal:  Nihon Rinsho       Date:  2015-09

Review 2.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 3.  Myasthenia gravis: subgroup classification and therapeutic strategies.

Authors:  Nils Erik Gilhus; Jan J Verschuuren
Journal:  Lancet Neurol       Date:  2015-10       Impact factor: 44.182

Review 4.  Does this patient have myasthenia gravis?

Authors:  Katalin Scherer; Richard S Bedlack; David L Simel
Journal:  JAMA       Date:  2005-04-20       Impact factor: 56.272

Review 5.  Treatment of Myasthenia Gravis in the Aged.

Authors:  Nuha M Alkhawajah; Joel Oger
Journal:  Drugs Aging       Date:  2015-09       Impact factor: 3.923

Review 6.  An update on laboratory diagnosis in myasthenia gravis.

Authors:  Joel Oger; Hans Frykman
Journal:  Clin Chim Acta       Date:  2015-08-01       Impact factor: 3.786

Review 7.  Future perspectives in target-specific immunotherapies of myasthenia gravis.

Authors:  Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

Review 8.  Myasthenia Gravis.

Authors:  Kelly G Gwathmey; Ted M Burns
Journal:  Semin Neurol       Date:  2015-10-06       Impact factor: 3.420

9.  Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study.

Authors:  J B Andersen; J F Owe; A Engeland; N E Gilhus
Journal:  Eur J Neurol       Date:  2014-04-09       Impact factor: 6.089

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.